An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors

PURPOSE: Patients with RAS-positive tumors respond poorly to chemotherapies and have a few treatment options. Salirasib is an oral RAS inhibitor that competitively blocks the membrane association of RAS proteins. The aim of this phase I multiple-ascending-dose clinical trial was to investigate the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuse, Junji, Kurata, Takayasu, Okano, Naohiro, Fujisaka, Yasuhito, Naruge, Daisuke, Shimizu, Toshio, Kitamura, Hiroshi, Iwasa, Tsutomu, Nagashima, Fumio, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105164/
https://www.ncbi.nlm.nih.gov/pubmed/29992354
http://dx.doi.org/10.1007/s00280-018-3618-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105164/
https://www.ncbi.nlm.nih.gov/pubmed/29992354
http://dx.doi.org/10.1007/s00280-018-3618-4

Ejemplares similares